This review examines the molecular structure of the NRF2-KEAP1 axis, synthesizing evidence regarding its efficacy in ischemia-reperfusion injury and diabetic cardiomyopathy, while assessing the mechanisms of pathway repression and the liabilities of indiscriminate activation. Here, KEAP1 is linked to diabetic cardiomyopathy.